title: Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.
abstract: OBJECTIVE
  To investigate the effect of 4 weeks of treatment with liraglutide on insulin dose and glycemic control in type 1 diabetic patients with and without residual β-cell function.
  
  
  METHODS
  Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied. All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy. Continuous glucose monitoring with identical food intake and physical activity was performed before (week 0) and during (week 4) treatment. Differences in insulin dose; HbA1c; time spent with blood glucose<3.9, >10, and 3.9-9.9 mmol/L; and body weight were evaluated.
  
  
  RESULTS
  Insulin dose decreased from 0.50±0.06 to 0.31±0.08 units/kg per day (P<0.001) in C-peptide-positive patients and from 0.72±0.08 to 0.59±0.06 units/kg per day (P<0.01) in C-peptide-negative patients treated with liraglutide but did not change with insulin monotherapy. HbA1c decreased in both liraglutide-treated groups. The percent reduction in daily insulin dose was positively correlated with β-cell function at baseline, and two patients discontinued insulin treatment. In C-peptide-positive patients, time spent with blood glucose<3.9 mmol/L decreased from 3.0 to 1.0 h (P=0.03). A total of 18 of 19 patients treated with liraglutide lost weight during treatment (mean [range] -2.3±0.3 kg [-0.5 to -5.1]; P<0.001). Transient gastrointestinal adverse effects occurred in almost all patients treated with liraglutide.
  
  
  CONCLUSIONS
  Treatment with liraglutide in type 1 diabetic patients reduces insulin dose with improved or unaltered glycemic control.
authors: Department of Endocrinology, Hvidovre University Hospital, and Department of Biomedical Sciences, the Panum Institute, University of Copenhagen, Copenhagen, Denmark. urd.kielgast@hvh.regionh.dk
authors: Urd
authors: U
authors: Kielgast
authors: Thure
authors: T
authors: Krarup
authors: Jens Juul
authors: JJ
authors: Holst
authors: Sten
authors: S
authors: Madsbad
references: Diabetes Care. 2009 Dec;32(12):2251-7
references: 19808924
references: J Clin Invest. 1998 Feb 1;101(3):515-20
references: 9449682
references: Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77
references: 19748064
references: Lancet. 2002 Mar 9;359(9309):824-30
references: 11897280
references: Acta Med Scand. 1979;205(5):385-7
references: 443076
references: Physiol Rev. 2007 Oct;87(4):1409-39
references: 17928588
references: Gut. 1999 Jan;44(1):81-6
references: 9862830
references: Diabetes Care. 1996 Jun;19(6):580-6
references: 8725855
references: BMC Endocr Disord. 2003 Apr 10;3(1):3
references: 12697069
references: Diabetes Obes Metab. 2012 Jun;14(6):531-8
references: 22226053
references: Diabetes Care. 1997 Mar;20(3):381-4
references: 9051391
references: Curr Diabetes Rev. 2009 Nov;5(4):266-75
references: 19925391
references: Diabetes Care. 2010 Jun;33(6):1294-6
references: 20332358
references: Diabetes Care. 2000 Jun;23(6):807-12
references: 10841001
references: Diabetes. 1995 Jun;44(6):626-30
references: 7789625
references: N Engl J Med. 1992 May 14;326(20):1316-22
references: 1348845
references: J Clin Endocrinol Metab. 2004 Jul;89(7):3469-73
references: 15240633
references: J Clin Endocrinol Metab. 2002 Mar;87(3):1239-46
references: 11889194
references: Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):491-9
references: 18542012